Share this article
Share this article
RADNOR, Pa., May 24, 2021 /PRNewswire/ The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ( ChemoCentryx ) on behalf of those who purchased or acquired ChemoCentryx common stock
between November 26, 2019 and May 3, 2021, inclusive (the Class Period ).
Investor Reminder: Investors who purchased or acquired ChemoCentryx common stock
during the Class Period may,
no later than July 6, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at[email protected];
Kessler Topaz Meltzer & Check, LLP Reminds ChemoCentryx, Inc Investors of Important Deadline in Securities Fraud Class Action Lawsuit
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ChemoCentryx, Inc – CCXI
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.
RADNOR, Pa., May 19, 2021 (GLOBE NEWSWIRE) The law firm of Kessler Topaz Meltzer & Check, LLP reminds ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against ChemoCentryx on behalf of those who purchased or acquired ChemoCentryx common stock
between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”).
Investor Reminder: Investors who purchased or acquired ChemoCentryx common stock
during the Class Period may,
no later than July 6, 2021
, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435;
Share this article
Share this article
NEW YORK, May 18, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ( ChemoCentryx or the Company ) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 4, 2021, the U.S. Food and Drug Administration ( FDA ) released a Briefing Document concerning ChemoCentryx s drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis. To support its New Drug Application for avacopan, ChemoCentryx relied primarily upon its Phase III ADVOCATE study. In the Briefing Document, the FDA wrote that [c]omplexities of the study design . . . raise questions about the i